Cancer Precision Medicine

Precision medicine is a treatment approach customised to each individual patient. Because no two cancers are precisely alike, therapies often need to be tailored to specific tumours and patients to be effective. In cancer, precision medicine uses specific information about a person’s tumour to help make a diagnosis, plan treatment, monitor treatment response, or make a prognosis.

In the research programme Cancer Precision Medicine, we aim to understand how factors such as genetics, epigenetics, molecular mechanisms, proteins, biomarkers, cellular processes, tumour biology and epidemiology can form a basis to find the best approach to prevent or treat the disease. Our research ranges all the way from bench to bedside.

Research groups

Panagiotis Baliakas – Molecular genetics of hematological malignancies

Johan Botling – Molecular tumour pathology

Jan Dumanski – Molecular oncology

Ingrid Glimelius – Clinical, epidemiological and tumour biology studies of different cancer forms

Helena Jernberg Wiklund – Targeting epigenetic regulators to develop novel therapeutic strategies and precision medicine in human haematological cancers

Birgitta Johansson – Caring sciences in oncology care

Cecilia Lindskog Bergström – A spatio-temporal single-cell type map of human tissues

Magnus Lindskog – Clinical and epidemiological studies to identify optimal treatment strategies for chemo-resistant cancers

Marika Nestor – Novel cancer-targeting strategies for improved molecular radiotherapy

Peter Nygren – New and individualised cancer treatment

Tobias Sjöblom – Finding and understanding cancer-causing molecular alterations

Bo Stenerlöw – Radiation biology and DNA repair

Vladimir Tolmachev – Scaffold protein-based radionuclide tumour targeting

Last modified: 2023-03-09